A S A S

A S A S is a pharmaceutical importer and buyer based in Colombia, specializing in the acquisition of finished pharmaceutical formulations from international suppliers, particularly from India. The company plays a pivotal role in the Colombian pharmaceutical distribution network by sourcing and importing a range of pharmaceutical products to meet the domestic market's needs. While specific details about its headquarters, parent company, and organizational structure are not publicly available, A S A S's operations are integral to the supply chain, ensuring the availability of essential medications within Colombia.

Information regarding A S A S's warehouse locations, logistics capabilities, and geographic coverage within Colombia is not publicly disclosed. However, given the company's focus on importing pharmaceutical products, it is likely that A S A S collaborates with established logistics providers to facilitate the efficient distribution of its products across the country. The company's reliance on international suppliers, particularly from India, suggests a well-coordinated logistics network to manage the importation and distribution processes effectively.

A S A S operates as a pharmaceutical importer and buyer within Colombia's pharmaceutical supply chain. Its primary function is to source and import finished pharmaceutical formulations from international suppliers, with a significant emphasis on products from India. By doing so, A S A S contributes to the diversification and availability of pharmaceutical products in the Colombian market, catering to various therapeutic needs.

A S A S's sourcing strategy exhibits a high degree of concentration, with a portfolio entirely composed of two products: Bleomycin and Vincristine. This singular focus on oncology medications indicates a strategic choice to specialize in a niche market segment, potentially allowing the company to develop expertise and strong relationships within this therapeutic area. The substantial import values—$96K for Bleomycin and $84K for Vincristine—reflect a stable demand and a consistent supply chain for these products. However, this concentration also poses risks; any disruptions in the supply chain, such as regulatory changes or supplier issues, could significantly impact A S A S's operations. The company's reliance on a limited number of products suggests a need for strategic planning to mitigate potential risks associated with such concentration.

A S A S's supply chain resilience is closely tied to its sourcing strategy, which is heavily dependent on a select group of Indian suppliers. The company's top suppliers include Venus Remedies Limited, Naprod Life Sciences Private Limited, and Aurobindo Pharma Limited, collectively accounting for a significant portion of the total import value. This concentrated supplier base may enhance operational efficiency and foster strong supplier relationships. However, it also exposes A S A S to potential risks, such as supply disruptions or changes in supplier policies. The company's focus on a limited number of formulations—131 unique formulations—indicates a streamlined product offering, which could be advantageous in terms of inventory management and regulatory compliance. To bolster supply chain resilience, A S A S may consider diversifying its supplier base and product portfolio, thereby reducing dependency on a narrow segment and enhancing its ability to adapt to market changes.

A S A S's concentrated sourcing pattern positions the company as a specialized player in the oncology pharmaceutical market within Colombia. This specialization allows A S A S to develop deep expertise and potentially secure favorable terms with its suppliers. For Indian exporters, this focus presents an opportunity to establish strong partnerships with A S A S, particularly if they can offer high-quality oncology products that meet the company's specific requirements. However, the limited product range also means that A S A S is highly sensitive to changes in the oncology market, such as shifts in treatment protocols or the introduction of new therapies. Indian exporters seeking to collaborate with A S A S should ensure their products align with the company's therapeutic focus and quality standards to capitalize on this strategic alignment.

In Colombia, the primary regulatory authority overseeing pharmaceutical products is the National Institute for Food and Drug Surveillance (INVIMA). INVIMA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products available in the Colombian market. The regulatory framework governing pharmaceutical imports includes Decree 677 of 1995, which outlines the sanitary registration requirements for drugs and biological products. This decree mandates that all pharmaceutical products imported into Colombia must undergo a registration process with INVIMA, ensuring they meet the necessary standards for public health. Additionally, Decree 1165 of 2019, as amended by Decree 360 of 2021, provides comprehensive guidelines on the importation of pharmaceutical products, detailing procedures for customs clearance, documentation, and compliance with health regulations. These regulations are designed to protect public health by ensuring that all pharmaceutical products entering Colombia are safe for consumption and effective in their intended use.

Importers of pharmaceutical products into Colombia must adhere to specific licensing requirements. They are required to register with the National Tax and Customs Directorate (DIAN) and obtain a Tax Identification Number (NIT). Additionally, importers must be registered in the Single Tax Registry (RUT) and have access to the Single Window for Foreign Trade (VUCE) platform. For products subject to special controls, such as controlled substances, importers must obtain prior approval from the Ministry of Commerce, Industry and Tourism (MinCIT) for the Import Registration Form or Import License. Furthermore, when applicable, importers must secure permits from pertinent government agencies, such as INVIMA for health-related products, before the cargo departs from the country of origin. Regarding Good Manufacturing Practice (GMP) certification, Colombia recognizes certifications from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from these recognized organizations to comply with Colombian regulations. Additionally, importers must obtain wholesale distribution authorization from INVIMA, which involves demonstrating compliance with storage, handling, and distribution standards to ensure the integrity of pharmaceutical products throughout the supply chain.

Pharmaceutical products imported into Colombia must meet specific quality and labeling requirements to ensure consumer safety and product efficacy. Batch testing is mandatory to verify the quality and consistency of each production batch, ensuring that products meet the specified standards. Stability requirements are also enforced to confirm that products maintain their efficacy and safety throughout their shelf life. Labeling must be in Spanish and include essential information such as the generic and commercial names, net weight or volume, weight or quantity of active ingredients, license number, lot control number, and expiration date. Additionally, labels must indicate "for sale under medical, dental or veterinary prescription" to inform consumers of the product's intended use. Serialization mandates may apply to facilitate traceability and prevent counterfeit products from entering the market, enhancing the overall safety and integrity of the pharmaceutical supply chain.

Between 2024 and 2026, Colombia implemented significant regulatory changes affecting pharmaceutical imports. Notably, Decree 659 of 2024 introduced the requirement for an Advanced Declaration, mandating that all importers file a declaration at least 48 hours before cargo arrives in Colombia. This measure aims to enhance customs controls and streamline the importation process. Failure to comply with this requirement can result in fines or seizure of goods. Additionally, Decree 1165 of 2019, as amended by Decree 360 of 2021, provided comprehensive guidelines on the importation of pharmaceutical products, detailing procedures for customs clearance, documentation, and compliance with health regulations. These regulatory changes underscore Colombia's commitment to strengthening its pharmaceutical import framework and ensuring the safety and efficacy of products entering the market.

A S A S's product strategy focuses exclusively on oncology medications, importing finished pharmaceutical formulations such as Bleomycin and Vincristine. This strategic focus aligns with the company's specialization in the oncology therapeutic area, catering to the specific needs of patients requiring cancer treatments. The decision to concentrate on these products may be driven by factors such as market demand, the company's expertise in oncology, and the potential for establishing strong supplier relationships within this niche segment. By focusing on a limited number of products, A S A S can streamline its operations, maintain a high level of product knowledge, and ensure the quality and efficacy of the medications it imports.

A S A S's sourcing strategy is characterized by a concentrated approach, importing finished pharmaceutical formulations exclusively from India. The company's top suppliers include Venus Remedies Limited, Naprod Life Sciences Private Limited, and Aurobindo Pharma Limited, indicating a preference for established Indian pharmaceutical manufacturers. This sourcing profile suggests a strategic choice to leverage India's robust pharmaceutical manufacturing capabilities, particularly in the oncology sector, to meet the specific needs of the Colombian market. By focusing on a select group of suppliers, A S A S can develop strong partnerships, ensure consistent product quality, and potentially negotiate favorable terms.

Based on its product mix, A S A S serves a specialized segment of the Colombian pharmaceutical market, focusing on oncology treatments. The company's exclusive importation of products like Bleomycin and Vincristine positions it as a niche supplier catering to the needs of healthcare providers and patients requiring cancer therapies. This market positioning allows A S A S to develop deep expertise in oncology,